AbbVie Q3 2026 Earnings: EPS More Than Doubles Year Over Year
AbbVie posted strong third-quarter 2026 results, with both GAAP and adjusted diluted EPS surging more than 100% despite a modest headwind from acquired IPR&D costs.
AbbVie reported diluted earnings per share of $2.37 on a GAAP basis for the third quarter of 2026, a gain of more than 100 percent compared to the same period a year earlier. Adjusted diluted EPS came in at $3.82, also more than doubling on a year-over-year basis, signaling broad-based profit momentum at the pharmaceutical giant.
Both figures were tempered slightly by an unfavorable impact of $0.11 per share tied to acquired in-process research and development charges and milestone expenses — costs that typically reflect ongoing deal activity and pipeline investments rather than core operational performance.
Read more Cboe Global Markets Posts Record EPS in Third Quarter 2026 →
The back-to-back triple-digit percentage gains in earnings underscore a significant recovery or growth cycle for AbbVie, which has been navigating the post-patent landscape for its former blockbuster immunology drug while building out a diversified portfolio of newer therapies. The adjusted EPS figure, which strips out certain non-cash and acquisition-related items, is generally the metric most closely tracked by Wall Street analysts.
The IPR&D and milestone charge, while modest on a per-share basis, highlights that AbbVie continues to invest aggressively in external research assets and licensing arrangements — a strategy the company has leaned on to sustain long-term revenue growth as competition in key therapeutic areas intensifies.
Continue reading at Earnings for the full financial tables and management commentary.
